CLX - The Clorox Company

NYSE - NYSE Delayed Price. Currency in USD
114.80
-0.08 (-0.07%)
At close: 4:02PM EDT

115.10 +0.30 (0.26%)
After hours: 6:42PM EDT

Stock chart is not supported by your current browser
Previous Close114.88
Open115.50
Bid0.00 x 0
Ask0.00 x 0
Day's Range114.01 - 115.93
52 Week Range114.01 - 150.40
Volume2,094,586
Avg. Volume1,229,672
Market Cap14.856B
Beta0.31
PE Ratio (TTM)18.94
EPS (TTM)6.06
Earnings DateMay 2, 2018
Forward Dividend & Yield3.84 (3.02%)
Ex-Dividend Date2018-04-24
1y Target Est139.07
Trade prices are not sourced from all markets
  • What Analysts Recommend For Church & Dwight Stock
    Market Realist7 hours ago

    What Analysts Recommend For Church & Dwight Stock

    Most analysts covering Church & Dwight (CHD) stock have recommended “hold,” despite the company’s strong sales and earnings performance in the past two quarters and upbeat guidance. Church & Dwight’s sales and adjusted earnings grew by double digits during the last reported quarter, and they are expected to sustain that momentum in 1Q18.

  • Why Church & Dwight’s Earnings Could Be Better Than Peers’?
    Market Realist8 hours ago

    Why Church & Dwight’s Earnings Could Be Better Than Peers’?

    Analysts expect Church & Dwight (CHD) to report strong sales and earnings growth in the upcoming quarter. Church & Dwight is expected to announce its 1Q18 results on May 3, 2018, and analysts expect the company’s top line to rise 11.5% YoY (year-over-year), more than peers’.

  • Why Church & Dwight Stock Fell ~6%
    Market Realist10 hours ago

    Why Church & Dwight Stock Fell ~6%

    Church & Dwight (CHD) stock fell ~6% on Friday, April 20, 2018, after being downgraded by Deutsche Bank to “hold” from “buy.” Its price target was lowered to $50 per share from $56. Investors are skeptical on the prospects of household and personal care product manufacturers, which are facing increased price competition, a challenging retail scenario, and margin headwinds.

  • ACCESSWIRE16 hours ago

    EX-Dividend Schedule: Clorox Raised its Dividend By 14%; Will Trade Ex-Dividend on April 24, 2018

    LONDON, UK / ACCESSWIRE / April 23, 2018 / Active-Investors has a free review on The Clorox Co. (NYSE: CLX) following the Company's announcement that it will begin trading ex-dividend on April 24, 2018. Active-Investors has initiated due-diligence on this dividend stock. If your portfolio includes dividend stocks, you have come to the right place for timely information.

  • How Analysts Reacted to PG’s 3Q18 Results
    Market Realist3 days ago

    How Analysts Reacted to PG’s 3Q18 Results

    Procter and Gamble (PG) saw improved sales and earnings performance in fiscal 3Q18. The company’s top and bottom line surpassed analysts’ expectations. However, the company’s soft organic sales growth rate and sluggish margins due to lower pricing and increased costs didn’t sit well with analysts.

  • Why Procter & Gamble’s 3Q18 Margins Disappointed Investors
    Market Realist3 days ago

    Why Procter & Gamble’s 3Q18 Margins Disappointed Investors

    Procter & Gamble (PG) continued to report sluggish margins in fiscal 3Q18. The company’s core gross margin fell 110 basis points to 49.4% in fiscal 3Q18 as lower pricing to drive volumes and increased cost pressure more than offset the benefits stemming from cost and productivity savings.

  • Procter & Gamble’s 3Q Sales Improved, but Challenges Persist
    Market Realist3 days ago

    Procter & Gamble’s 3Q Sales Improved, but Challenges Persist

    Procter & Gamble (PG) reported net sales of $16.3 billion, a rise of 4.3% YoY (year-over-year), which exceeded analysts’ expectations. As expected, Procter & Gamble’s top line benefitted from improved volumes and favorable currency rates. Also, the improved mix contributed 1% to the net sales growth rate.

  • Why Procter & Gamble’s Fiscal 3Q18 EPS Didn’t Impress Investors
    Market Realist3 days ago

    Why Procter & Gamble’s Fiscal 3Q18 EPS Didn’t Impress Investors

    Procter & Gamble (PG) reported adjusted earnings of $1.00 per share in fiscal 3Q18, which came in ahead of analysts’ estimate of $0.98 and increased 4.2% YoY (year-over-year). Moreover, Procter & Gamble has now surpassed analysts’ earnings expectations in the past 12 quarters. However, what didn’t sit well with investors was the company’s low EPS growth rate, especially given the benefits from favorable currency rates, the low tax rate environment, and strong productivity savings.

  • What Analysts Recommend for Colgate-Palmolive Stock
    Market Realist4 days ago

    What Analysts Recommend for Colgate-Palmolive Stock

    Most of the analysts covering Colgate-Palmolive (CL) have maintained “hold” ratings on its stock as a soft sales environment, a moderating category growth rate, increased competition, and margin headwinds have kept them on the sidelines.

  • ACCESSWIRE4 days ago

    Today’s Research Reports on Stocks to Watch: The Clorox Company and Procter & Gamble

    NEW YORK, NY / ACCESSWIRE / April 20, 2018 / The Clorox Company and Procter & Gamble both sank to new lows on Thursday. The Clorox company saw its shares decrease after a downgrade from a Morgan Stanley ...

  • What Could Pressure Colgate-Palmolive’s 1Q18 Margins?
    Market Realist4 days ago

    What Could Pressure Colgate-Palmolive’s 1Q18 Margins?

    As for Colgate-Palmolive (CL), the company’s profit margins are likely to be adversely impacted by inflation in commodity prices, including resins and pulp. Higher logistics costs and increased advertising spending to support new product launches and drive market share are also expected to hurt its margins. Higher volumes, a focus on productivity savings, and SKU optimization are likely to support its margins.

  • Will Colgate-Palmolive Sustain Sales Momentum in 1Q18?
    Market Realist4 days ago

    Will Colgate-Palmolive Sustain Sales Momentum in 1Q18?

    Analysts expect Colgate-Palmolive (CL) to report sales of $4.0 billion in 1Q18, which represents a YoY (year-over-year) rise of 6.6%. The graph above shows that Colgate-Palmolive’s sales are showing an improving trend thanks to favorable currency rates and improvements in its volumes. Colgate-Palmolive’s top line is likely to benefit from improvements in volumes driven by new product launches in the oral and personal care segments backed by increased investments in advertising.

  • Why Align Technology, Taiwan Semiconductor Manufacturing, and Clorox Slumped Today
    Motley Fool4 days ago

    Why Align Technology, Taiwan Semiconductor Manufacturing, and Clorox Slumped Today

    Find out why these stocks led the market lower.

  • Will Colgate-Palmolive’s Earnings See Growth in 1Q18?
    Market Realist4 days ago

    Will Colgate-Palmolive’s Earnings See Growth in 1Q18?

    Colgate-Palmolive’s (CL) earnings have remained flat over the past two quarters as benefits from currency tailwinds, improved volumes, and cost savings have been offset by higher raw material and packaging costs, lower pricing, and advertising spending. What could drive Colgate-Palmolive’s 1Q18 EPS? Colgate-Palmolive’s bottom line is expected to benefit from an improvement in its volumes.

  • InvestorPlace4 days ago

    Procter & Gamble Co Stock Continues to Struggle Despite Earnings Beat

    Procter & Gamble Co (NYSE:PG) stock took a hit following its earnings announcement. Although the company beat on both revenue and net income, earnings guidance disappointed Wall Street. Most of its peers in the consumer defensive sector also saw stock price drops on slower-than-expected growth.

  • Will Colgate-Palmolive’s 1Q18 Earnings Lift Its Stock?
    Market Realist4 days ago

    Will Colgate-Palmolive’s 1Q18 Earnings Lift Its Stock?

    Colgate-Palmolive (CL) is set to announce its 1Q18 earnings on April 27, 2018. Analysts expect the company’s top line to continue to improve driven by higher volumes and increased market share. New product launches and higher advertising spending are likely to support the company’s volumes.

  • CNBC4 days ago

    Clorox shares drop 5% after Morgan Stanley downgrades, says consumers shifting to smaller brands

    Morgan Stanley's Dara Mohsenian cuts his rating on Clorox to underweight from equal weight and slashed his price target to $116 a share from $128. Mohsenian says some of the challenges Clorox faces are pricing pressures and a shift away from "large established brands towards smaller brands" by consumers. Given these factors, "we believe consensus expectations for CLX are too high on both organic sales growth and gross margins over the next few years," Mohsenian notes.

  • Barrons.com4 days ago

    Clorox, P&G, Unilever Get Clipped

    Packaged food, beverages, tobacco and the rest of consumer staples haven't rewarded investors lately (but don't say we didn't warn you). Today, big household product makers are weighing on the sector.  Procter & Gamble (PG) is falling on Thursday following its fiscal third-quarter earnings report. The maker of personal-care products earned $1 a share, a penny ahead of estimates, while revenue climbed 4.3% year-over-year to $16.28 billion, squeaking past the $16.22 billion consensus estimate.

  • PR Newswire5 days ago

    Clorox Announces May 8 Webcast of Company Presentation at Goldman Sachs Global Staples Forum

    OAKLAND, Calif. , April 19, 2018 /PRNewswire/ -- The Clorox Company (NYSE: CLX) announced today that Lyne Brown, vice president of e-commerce, will be a featured speaker at the Goldman Sachs Global Staples ...

  • What Analysts Suggest for Kimberly-Clark Stock?
    Market Realist7 days ago

    What Analysts Suggest for Kimberly-Clark Stock?

    Kimberly-Clark (KMB) is expected to sustain its sales momentum in 1Q18, thanks to anticipated growth in volumes. Moreover, the company’s bottom line is projected to benefit from cost savings and a lower tax rate. However, most analysts prefer to maintain a “hold” rating on Kimberly-Clark stock, given the soft sales environment and near-term margin headwinds.

  • Why Kimberly-Clark’s Valuation Multiple Is Low
    Market Realist8 days ago

    Why Kimberly-Clark’s Valuation Multiple Is Low

    Kimberly-Clark (KMB) stock is trading at a forward PE (price-to-earnings) multiple of 15.2x, which is about 26% lower than the peer group average of 20.6x. Moreover, the company’s valuation multiple is also lower than the S&P 500 Index (SPY), which is trading at a forward PE ratio of 17.1x as of April 12.

  • Why Kimberly-Clark’s Margins Could Remain Pressured in Q1
    Market Realist8 days ago

    Why Kimberly-Clark’s Margins Could Remain Pressured in Q1

    Kimberly-Clark’s (KMB) profit margins are expected to remain muted, given the headwinds stemming from lower net selling prices and inflation in commodities and transportation costs. Kimberly-Clark’s promotional spending, as a result of soft product demand and increased competitive activity, is resulting in lower net selling prices. In turn, lower prices are affecting margins.

  • Will Low Birth Rates and Pricing Hurt Kimberly-Clark’s Sales?
    Market Realist8 days ago

    Will Low Birth Rates and Pricing Hurt Kimberly-Clark’s Sales?

    Kimberly-Clark’s (KMB) top line has been affected by lower pricing in the United States amid increased competition and a moderating category growth rate. Despite challenges, analysts expect Kimberly-Clark to sustain its sales momentum in 1Q18, led by improvements in volumes. Kimberly-Clark’s top line is expected to benefit from improvement in volumes, primarily in the personal care segment, led by gains from its joint venture in India.

  • Will Cost Savings Drive Kimberly-Clark’s Q1 Earnings Higher?
    Market Realist10 days ago

    Will Cost Savings Drive Kimberly-Clark’s Q1 Earnings Higher?

    Kimberly-Clark (KMB) is expected to announce its 1Q18 earnings on April 23. Analysts expect Kimberly-Clark to report adjusted earnings of $1.71 per share, which reflects YoY (year-over-year) growth of 8.9%. Improved sales and increased cost savings are expected to support Kimberly-Clark’s earnings growth.

  • Will Lower Pricing and Higher Costs Keep Hurting KMB?
    Market Realist10 days ago

    Will Lower Pricing and Higher Costs Keep Hurting KMB?

    Kimberly-Clark (KMB) is expected to announce its 1Q18 results on April 23. Analysts expect the company’s sales to sustain their momentum, led by improvements in volumes. Innovation-led products and brand investments are expected to support sales. Moreover, gains from the India joint venture should further drive net sales growth. However, lower net selling prices—due to promotional spending amid increased competition—are likely to remain a drag.